Literature DB >> 24389640

Methamphetamine-like discriminative-stimulus effects of nicotinic agonists.

Rajeev I Desai1, Jack Bergman.   

Abstract

Nicotine was recently shown to engender d-methamphetamine (MA)-like discriminative-stimulus effects in rats, which may be indicative of shared psychomotor stimulant properties. To further investigate such overlapping discriminative-stimulus effects, nicotinic agonists varying in efficacy and selectivity were studied in squirrel monkeys that discriminated a moderate intramuscular dose of MA (0.1 mg/kg) from vehicle. These included α4β2-selective ligands that may vary in efficacy from relatively high [nicotine, (+)- and (-)-epibatidine] to relatively low [isoarecolone, varenicline, (-)-cytisine, (-)-lobeline] and the α7-selective ligands anabaseine and anabasine. Results show that nicotine, (+)-epibatidine, and (-)-epibatidine substituted fully for MA, whereas the highest doses of other nicotinic agonists produced intermediate levels of MA-like effects (isoarecolone, anabaseine, anabasine, and varenicline) or did not substitute for MA [(-)-cytisine and (-)-lobeline]. The relative potencies of nicotinic agonists, based on effective dose50 (ED50) values, corresponded more closely with their relative affinities at α4β2 than at α7 receptors. Regardless of selectivity or efficacy, nicotinic agonists also were observed to produce untoward effects, including salivation and emesis during or after experimental sessions. In pretreatment studies, the α4β2-selective antagonist dihydro-β-erythroidine hydrobromide (DHβE) (0.032 and 0.1 mg/kg) and the partial agonists varenicline (0.0032-0.1 mg/kg) and (-)-cytisine (0.032 and 0.1 mg/kg) surmountably antagonized (>10-fold rightward shift) nicotine's MA-like effects but were ineffective in blocking nicotine's emetic effects. Overall, our results show that 1) MA-like discriminative-stimulus effects of nicotinic agonists likely are mediated through α4β2 nicotinic acetylcholine receptor actions, and 2) nicotinic α4β2 partial agonists, like the nicotinic antagonist DHβE, can reduce MA-like behavioral effects of nicotine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24389640      PMCID: PMC3935143          DOI: 10.1124/jpet.113.211235

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

Review 1.  Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics.

Authors:  M W Decker; J D Brioni; A W Bannon; S P Arneric
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

2.  (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.

Authors:  J P Sullivan; M W Decker; J D Brioni; D Donnelly-Roberts; D J Anderson; A W Bannon; C H Kang; P Adams; M Piattoni-Kaplan; M J Buckley
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

3.  Clozapine attenuates the discriminative stimulus properties of (-)-nicotine.

Authors:  J D Brioni; D J Kim; A B O'Neill; J E Williams; M W Decker
Journal:  Brain Res       Date:  1994-04-18       Impact factor: 3.252

4.  Epibatidine, a potent analgetic and nicotinic agonist.

Authors:  B Badio; J W Daly
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

5.  Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats.

Authors:  C Reavill; C E Spivak; I P Stolerman; J A Waters
Journal:  Neuropharmacology       Date:  1987-07       Impact factor: 5.250

6.  Further studies on nicotine-induced conditioned place preference in the rat.

Authors:  P J Fudala; E T Iwamoto
Journal:  Pharmacol Biochem Behav       Date:  1986-11       Impact factor: 3.533

7.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain.

Authors:  D J Anderson; S P Arneric
Journal:  Eur J Pharmacol       Date:  1994-03-03       Impact factor: 4.432

8.  Pharmacological effects of epibatidine optical enantiomers.

Authors:  M I Damaj; K R Creasy; A D Grove; J A Rosecrans; B R Martin
Journal:  Brain Res       Date:  1994-11-21       Impact factor: 3.252

9.  Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes.

Authors:  C M de Fiebre; E M Meyer; J C Henry; S I Muraskin; W R Kem; R L Papke
Journal:  Mol Pharmacol       Date:  1995-01       Impact factor: 4.436

10.  Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21.

Authors:  G W Arendash; G J Sengstock; P R Sanberg; W R Kem
Journal:  Brain Res       Date:  1995-03-20       Impact factor: 3.252

View more
  11 in total

1.  Influence of experimental history on nicotine self-administration in squirrel monkeys.

Authors:  Rajeev I Desai; Katherine A Sullivan; Stephen J Kohut; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-04-04       Impact factor: 4.530

2.  Nicotinic effects of tobacco smoke constituents in nonhuman primates.

Authors:  Rajeev I Desai; Michelle R Doyle; Sarah L Withey; Jack Bergman
Journal:  Psychopharmacology (Berl)       Date:  2016-02-19       Impact factor: 4.530

Review 3.  Interactions between nicotine and drugs of abuse: a review of preclinical findings.

Authors:  Stephen J Kohut
Journal:  Am J Drug Alcohol Abuse       Date:  2016-09-02       Impact factor: 3.829

4.  Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

5.  Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.

Authors:  Sarah L Withey; Michelle R Doyle; Jack Bergman; Rajeev I Desai
Journal:  J Pharmacol Exp Ther       Date:  2018-05-21       Impact factor: 4.030

6.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

7.  Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily.

Authors:  Colin S Cunningham; Megan J Moerke; Martin A Javors; F Ivy Carroll; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

8.  Methamphetamine-like discriminative stimulus effects of bupropion and its two hydroxy metabolites in male rhesus monkeys.

Authors:  Matthew L Banks; Douglas A Smith; Bruce E Blough
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

9.  The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in male rats.

Authors:  Steven T Pittenger; Scott T Barrett; Shinnyi Chou; Rick A Bevins
Journal:  Behav Brain Res       Date:  2016-12-08       Impact factor: 3.332

10.  Effects of Nicotine Metabolites on Nicotine Withdrawal Behaviors in Mice.

Authors:  Sagi Elhassan; Deniz Bagdas; M Imad Damaj
Journal:  Nicotine Tob Res       Date:  2017-06-01       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.